个人简介
李晓波,博士,2009年毕业于北京协和医学院生物化学与分子生物学系。美国Mitchell肿瘤研究所从事博士后研究近4年(2009年-2013年)。2013年归国到哈尔滨医科大学基础医学院病理教研室工作,技术职称为副研究员。2016年破格晋升为研究员。现任病理教研室副主任,硕士研究生导师,黑龙江省生物工程学会理事,并担任多个国际杂志的编委及审稿人。主要研究方向为恶性肿瘤的预防和治疗,以及基于大数据的肿瘤精准医疗开发与转化研究。目前已经在《CellDeath&Differ》、《Oncogene》、《Autophagy》以及《NuclAcidsRes》等高水平杂志发表SCI论文40多篇,论文总引用次数超过400。
研究领域
恶性肿瘤的预防和治疗,以及基于大数据的肿瘤精准医疗开发与转化研究
近期论文
查看导师最新文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
Lili Ren, Xiaobo Li*, Rui Su*. Targeting METTL14 and RNA methylation to treat osteosarcoma. EBioMedicine. 2022;82:104190. (IF2021=11.205)
Xiaobo Li, Yuanyuan Zhu, Xiao Zhang, Xiang An, Mingjiao Weng, Jiaqi Shi, Song Wang, Caiqi Liu, Shengnan Luo, Tongsen Zheng. An alternatively spliced STING isoform in cytomembrane with its C-terminus outside cells senses extracellular cGAMP. Journal of Clinical Investigation 2022;132(3):e144339. (IF2021=19.456 )
Weiwei Yang, Jing Li, Minghui Zhang, Haichuan Yu, Yuan Zhuang, Lingyu Zhao, Lili Ren, Jinan Gong, Hongjie Bi, Lixuan Zeng, Yang Xue, Jinjin Yang, Yan Zhao, Shuoshuo Wang, Shuangshu Gao, Zitong Fu, Dongze Li, Jinxing Zhang, Tianzhen Wang, Ming Shan, Bo Tang, Xiaobo Li. Elevated expression of the rhythm gene NFIL3 promotes the progression of TNBC by activating NF-κB signaling through suppression of NFKBIA transcription. Journal of Experimental & Clinical Cancer Research. 2022;41(1):67.(IF2021=12.658)
Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X*. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019;18(1):152. (IF2019=15.302;IF2021=41.444)
An X, Zhu Y, Zheng Z, Wang T, He Y, Zhang L, Yang W, Zhao R, Hao D, Li X*. An Analysis of the Expression and Association with Immune Cell Infiltration of the cGAS/STING Pathway in Pan-Cancer. Mol Ther Nucleic Acids. 2019 Mar 1;14:80-89. (IF2019=7.032;IF2021=10.183)
Wang T, Hao D, Yang S, Ma J, Yang W, Zhu Y, Weng M, An X, Wang X, Li Y, Wu D, Tang J, Yang C, He Y, Zhang L, Jin X, Wang G, Li Z, Zheng T, Meng H, Feng Y, Li X*. miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer. Cell Death Dis. 2019, 10(7):495. (IF=8.304;IF2021=9.685)
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. Wang G, Xu D, Zhang Z, Li X, Shi J, Sun J, Liu HZ, Li X*, Zhou M*, Zheng T*. NPJ Precis Oncol. 2021;5(1):56. (IF2021=10.092)
Double-edged effects of interferons on the regulation of cancer-immunity cycle. Xiao Zhao, Song Wang, Yuanyuan Zhu, Minghui Zhang, Yan Zhao, Zhengbin Yan, Qiuxu Wang*, Xiaobo Li*. Oncoimmunology. 2021;10(1):e1929005. (IF2021=7.723)